PPT-Lopinavir and atazanavir

Author : phoebe-click | Published Date : 2018-12-04

in pregnancy preterm delivery rates infant outcomes and virological efficacy Dr Melissa Perry Guys amp St Thomas NHS Foundation Trust London United Kingdom Low

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Lopinavir and atazanavir" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Lopinavir and atazanavir: Transcript

in pregnancy preterm delivery rates infant outcomes and virological efficacy Dr Melissa Perry Guys amp St Thomas NHS Foundation Trust London United Kingdom Low rates of mothertochild transmission of HIV . HIV Malaria Co-infection. M . Lamorde. MRCP, PhD. Malaria: major cause of morbidity and mortality in tropics. Treatment: artemisinin derivatives are critical for eradication of . plasmodium falciparum . M Harris, . S Guillemi. , K Chan, B Yip. ,. . M Hull, V Dias Lima, R Hogg, J . Montaner. Abstract #: WEAB0202. Organ Dysfunction in HIV: It's . Complicated. Wednesday, 3 July 2013 14:30-16:. 00. Session . TARV. JHÓSEP ANDRÉS BLANCO MEJÍA. Interno Junior Farmacología Clínica. Universidad de La Sabana. CONTENIDO. Presentación de caso clínico. Consideraciones . farmacoterapéuticas. Recomendaciones. M. edications. in . Paediatrics. Dr Leon J. Levin. Head - . Paediatric. HIV . Programmes. Right to Care. New Regimens for DOH and Private Sector in SA. . 0-3 years. >3years and >10 kg. . 1. Data expressed as mean (n=3) ± SD. . RTV: ritonavir; LPV: . lopinavir. ; ATV: . atazanavir. . . *. *. †. †. *. *. †. †. †. Figure 2. Lipid accumulation in differentiating 3T3-F442A (A) and primary human adipocytes (B) following incubation with protease inhibitors with/without . Paul Reynolds, PharmD, BCCCP. Matthew Miller, PharmD, BCIDP. Gina Moore, PharmD, MBA. March 20, 2020. Learning Objectives. Identify the unique clinical and epidemiological characteristics of Coronavirus (COVID-19) in the spectrum of viral clinical illnesses and previous Coronavirus (SARS, MERS) and non-Coronavirus (influenza, common cold) related illnesses. 2 NRTIs in Treatment-Experienced. M97-765 Trial. Lopinavir. -RTV + . Nevirapine. + 2 NRTIs in Treatment-Experienced . M97-765: . Study Design. Source. : . Benson CA, et al. . J . Infect. . Dis. . 2002;185:599-607.. AI424-043 . Study. Atazanavir vs. Lopinavir-ritonavir in Previous PI Failure . AI424-043. : Study Design. Source: . Cohen C, et al. . Curr Med Res Opin. . 2005;21:. 1683-92.. Atazanavir 400 mg once daily + 2 NRTIs. Lopinavir. -RTV in Treatment Experienced. TITAN Trial. Darunavir/. r . versus Lopinavir/r in Treatment-Experienced . TITAN. : Study Design. Source: . Madruga. JV, et al. Lancet. 2007;370:49-58. . Darunavir. R. itonavir to Raltegravir. SWITCHMRK 1 & 2 Trials. Switching from Lopinavir-Ritonavir to Raltegravir. SWITCHMRK 1 & 2 Trials: Study Design. Source: . Eron. JJ, et al. Lancet. 2010;375:396-407.. Study 105. Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2). Study 105: Study Design. Source: . Elion. R, et al. AIDS. 2011;25:1881-6. . Background. : Randomized, partially placebo-controlled, double-blind phase 2 trial to compare the safety and efficacy of cobicistat and ritonavir as pharmacokinetic enhancers administered with atazanavir and fixed-dose tenofovir DF-emtricitabine in treatment-naïve adults with HIV infection.

Download Document

Here is the link to download the presentation.
"Lopinavir and atazanavir"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.